The Latest Trading Price of Natco Pharma Ltd is ₹ 1095 as of 30 Apr 15:30
. The P/E Ratio of Natco Pharma Ltd changed from 34.2 on March 2021 to 7.6 on March 2025 . This represents a CAGR of -25.98% over 5 yearsThe P/E Ratio of Pfizer Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Natco Pharma Ltd changed from ₹ 15045 crore on March 2021 to ₹ 14287 crore on March 2025 . This represents a CAGR of -1.03% over 5 yearsThe Market Cap of Pfizer Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Natco Pharma Ltd for the Dec '25 is ₹ 705.4 crore as compare to the Sep '25 revenue of ₹ 1463 crore. This represent the decline of -51.78% The revenue of Pfizer Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Natco Pharma Ltd for the Dec '25 is ₹ 216.8 crore as compare to the Sep '25 ebitda of ₹ 679.2 crore. This represent the decline of -68.08% The ebitda of Pfizer Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Natco Pharma Ltd changed from ₹ 668.5 crore to ₹ 140.4 crore over 7 quarters. This represents a CAGR of -59.01%
The net profit of Pfizer Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0%
The Dividend Payout of Natco Pharma Ltd changed from 30.96 % on March 2021 to 5.8 % on March 2025 . This represents a CAGR of -28.46% over 5 yearsThe Dividend Payout of Pfizer Ltd changed from 32.18 % on March 2021 to 98.34 % on March 2025 . This represents a CAGR of 25.03% over 5 years .
About Natco Pharma Ltd
Natco Pharma Limited was originally incorporated on 19 September 1981 as private limited company as 'Natco Fine Pharmaceuticals Private Limited'.
The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation dated 30 December 1994 issued by the RoC, Andhra Pradesh.
Natco Pharma is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
The Company's focus is primarily on niche therapeutic areas and complex products.
It sells products in over 40 countries.
FDF products are sold in the United States, India, Europe and the rest of the world (RoW).
About Pfizer Ltd
Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 business categories.
It has its own manufacturing facility at Goa and Thane.
It has the distinction of being the first pharmaceutical company in India to start clinical research.
The Company sells products in nearly 185 countries having 43 manufacturing sites globally.
FAQs for the comparison of Natco Pharma Ltd and Pfizer Ltd
Which company has a larger market capitalization, Natco Pharma Ltd or Pfizer Ltd?
Market cap of Natco Pharma Ltd is 19,627 Cr while Market cap of Pfizer Ltd is 21,538 Cr
What are the key factors driving the stock performance of Natco Pharma Ltd and Pfizer Ltd?
The stock performance of Natco Pharma Ltd and Pfizer Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Natco Pharma Ltd and Pfizer Ltd?
As of May 4, 2026, the Natco Pharma Ltd stock price is INR ₹1095.85. On the other hand, Pfizer Ltd stock price is INR ₹4708.15.
How do dividend payouts of Natco Pharma Ltd and Pfizer Ltd compare?
To compare the dividend payouts of Natco Pharma Ltd and Pfizer Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.